Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04699838
Title Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Muhammad Furqan

lung small cell carcinoma


Carboplatin + Ceralasertib + Durvalumab + Etoposide

Ceralasertib + Cisplatin + Durvalumab + Etoposide

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.